Form 4: Avalo Therapeutics CBO Granted Stock Options

Avalo Therapeutics' Chief Business Officer, Taylor Boyd, was granted 95,000 stock options with an exercise price of $17.64.

Summary

• Taylor Boyd, Chief Business Officer of Avalo Therapeutics, Inc. (AVTX), acquired 95,000 stock options.
• The transaction date for the option grant was February 26, 2026.
• The exercise price for these stock options is $17.64 per share.
• The options vest twenty-five percent (25%) on February 26, 2027, with the remaining portion vesting in equal monthly installments over the subsequent three years.
• Vesting is contingent upon Taylor Boyd's continued service to the company.
• The expiration date for these stock options is February 26, 2036.
• Following this transaction, Taylor Boyd beneficially owns 95,000 derivative securities directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a generally positive event for corporate governance, as it aligns management incentives with shareholder value. However, it is a routine compensation disclosure and not directly indicative of operational performance or significant new developments.

Positives

• The grant of stock options aligns the Chief Business Officer's financial interests with those of shareholders, incentivizing long-term company performance.
• This compensation structure is a common method for retaining key executives and motivating them to increase shareholder value.

Negatives

• The exercise of these options in the future could lead to dilution for existing shareholders, although this is a standard aspect of equity compensation plans.

Risks

• The value of the stock options is dependent on the future market price of Avalo Therapeutics' common stock exceeding the $17.64 exercise price.
• Vesting of the options is subject to the reporting person's continued service, meaning unvested options would be forfeited upon departure.

Future Outlook

This filing does not contain specific forward-looking statements or guidance regarding the company's financial performance or strategic direction, beyond the vesting schedule of the granted options.

Industry Context

StockSavvy.ai notes that the grant of stock options to key executives like the Chief Business Officer is a standard practice across the biotechnology and pharmaceutical industries. This form of compensation is widely used to attract, retain, and motivate talent by linking their personal financial success to the company's long-term stock performance.

Comparison to Industry Standards

• Executive stock option grants are a common component of compensation packages in the biotech sector, comparable to practices at companies like Moderna, BioNTech, or Regeneron, which frequently use equity to incentivize leadership.
• The vesting schedule, with an initial cliff and subsequent monthly installments over three years, is a typical structure designed to encourage long-term commitment and performance, aligning with global benchmarks for executive retention.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from increased alignment of executive interests with long-term stock performance.
• Chief Business Officer (Taylor Boyd): Receives significant equity compensation, incentivizing continued service and efforts to increase company value.

Next Steps

• The stock options will begin vesting on February 26, 2027, with subsequent monthly vesting over the following three years, subject to continued service.

Key Dates

Keywords

Avalo Therapeutics, AVTX, Stock Option, Insider Transaction, Executive Compensation, Form 4, Taylor Boyd, Chief Business Officer